Literature DB >> 17379587

Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients.

K Takemoto1, J Kato, M Kuriyama, T Nawa, M Kurome, H Okada, K Sakaguchi, Y Shiratori.   

Abstract

BACKGROUND: The effectiveness of leukocytapheresis against ulcerative colitis has been reported. However, the efficacy of this therapy for steroid-resistant ulcerative colitis patients has hardly been examined. AIMS: The aims of this study are to evaluate the efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients and to identify clinical factors that predict the efficacy of this therapy for these patients.
METHODS: Clinical factors of 71 steroid-resistant ulcerative colitis patients who underwent leukocytapheresis analysed.
RESULTS: Of those analysed, 53 (75%) patients showed an initial response to leukocytapheresis. Among cases with initial response, however, only 19 (27%) patients maintained remission for more than 6 months. Steroid-dependent course (Odds ratio =5.53, 95% confidence interval; 1.24-24.73) and a high C-reactive protein degree (Odds ratio=1.6, confidence interval; 1.09-2.35) were predictors of initial response to leukocytapheresis. Rapid response, which means remission induction within three leukocytapheresis sessions, was the only predictor of maintenance of remission for more than 6 months after successful leukocytapheresis therapy (odds ratio=8.01, confidence interval; 1.08-59.37).
CONCLUSIONS: Leukocytapheresis was effective for steroid-resistant ulcerative colitis patients. However, relapse was frequently observed within short periods after the initial response to this therapy. Patients without a rapid response should be treated with alternative or additional therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379587     DOI: 10.1016/j.dld.2007.01.010

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis.

Authors:  Brigitte Habermalz; Stefan Sauerland
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

2.  Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis.

Authors:  Valeria D'Ovidio; Donatella Meo; Angelo Viscido; Giampaolo Bresci; Piero Vernia; Renzo Caprilli
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

3.  Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease.

Authors:  Chiara De Cassan; Edoardo Savarino; Piero Marson; Tiziana Tison; Giorgia Hatem; Giacomo Carlo Sturniolo; Renata D'Incà
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 4.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

5.  Leukocyte apheresis in the management of ulcerative colitis.

Authors:  Ahmed Helmy; Maheeba Abdulla; Ingvar Kagevi; Khalid Al Kahtani
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.